![Ed Gemo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ed Gemo
Director Técnico/Científico/I+D en TURG POIN .
Cargos activos de Ed Gemo
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TURG POIN | Director Técnico/Científico/I+D | - | - |
Historial de carrera de Ed Gemo
Antiguos cargos conocidos de Ed Gemo.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
HALOZYME THERAPEUTICS, INC. | Director Técnico/Científico/I+D | - | 01/01/2020 |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Director Técnico/Científico/I+D | - | - |
INTERMUNE INC | Director Técnico/Científico/I+D | - | - |
Formación de Ed Gemo.
Brooklyn College | Undergraduate Degree |
Pace University | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Chief Tech/Sci/R&D Officer | 4 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
InterMune, Inc.
![]() InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Turning Point Therapeutics, Inc.
![]() Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Ed Gemo
- Experiencia